

Inclisiran (Leqvio®) in Patients With Atherosclerotic Vascular Disease and/or Heterozygous Familial Hypercholesterolemia Treated in Spain: the INSPIRE Study

NCT06958315

Status RECRUITING
Sponsor Novartis Pharmaceuticals
Enrollment 200 participants

Key Eligibility Criteria

Inclusion (5)

- Aged e 18 years.
- Written signed informed consent form (ICF).
- Patients with a confirmed clinical indication for inclisiran who have received the first dose of inclisiran, following clinical judgement, at least 2 months prior to the inclusion in the study.
- Available assessment of LDL-C levels (mg/dL) within 6 months before inclisiran initiation. The measurement of LDL-C levels must be done after one month of stable LLT and without any modification from the testing up to inclisiran initiation.
- Statin-intolerant patients are eligible if they had documented side effects on e2 statins, including one at the lowest dose.

Exclusion (1)

- \. Participating in a clinical trial of a treatment that could modify LDL-C levels during the observational period of the study.

Locations (19 total)

Novartis Investigative Site, Cadiz, Andalusia, Spain
Novartis Investigative Site, Granada, Andalusia, Spain
Novartis Investigative Site, Huelva, Andalusia, Spain
... and 16 more locations